NVAX - NASDAQ
Novavax, Inc.
$10.57
+3.6%Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
At a Glance
Live Snapshotnvax
Property, Plant, and Equipment (Net)
Last Annual Value
67.70M
3-Year CAGR
-45%
5-Year CAGR
-18%
10-Year CAGR
8%
Novavax, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)
| Company | Property, Plant, and Equipment (Net) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Novavax, Inc. NASDAQ:NVAX | 67.70M | -48.3% | -21.6% | 5.4% | |
 Precigen, Inc. NASDAQ:PGEN | 18.44M | 9.3% | -0.1% | -11.8% | |
 Terns Pharmaceuticals, Inc. NASDAQ:TERN | 884.00K | -4.9% | -3.3% | N/A | |
 Zenas BioPharma, Inc. NASDAQ:ZBIO | 1.39M | 11.0% | N/A | N/A | |
 Nektar Therapeutics NASDAQ:NKTR | 5.00M | -48.6% | -51.0% | -22.7% | |
 Trevi Therapeutics, Inc. NASDAQ:TRVI | 855.00K | -18.1% | 36.0% | 67.2% | |
 Intellia Therapeutics, Inc. NASDAQ:NTLA | 123.63M | -5.9% | 4.3% | 27.8% | |
 Upstream Bio, Inc. NASDAQ:UPB | 2.37M | 127.1% | N/A | N/A | |
 ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 9.07M | -8.9% | 30.3% | N/A |
Novavax, Inc. Fair Value Envelope
Related Guides
Continue your NVAX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.